Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFRwith IC50of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2and ERBB4with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2.
Price | 1.482,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFRwith IC50of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2and ERBB4with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2. |